Exhibit 99.2
BRISTOL-MYERS SQUIBB COMPANY
DOMESTIC* NET SALES BY PRODUCT
QUARTERLY SALES TREND ANALYSIS
($ in millions)
2006 | 2007 | % Change | % Change in U.S. Total Prescription**** | |||||||||||||||||||||||||||||||||||||||||||||
1st Qtr | 2nd Qtr | 6 Months | 3rd Qtr | 9 Months | 4th Qtr | Year | 1st Qtr | 2nd Qtr | 6 Months | 3rd Qtr | 9 Months | 4th Qtr | Year | Qtr vs. Qtr | YTD vs. YTD | Qtr vs. Qtr | YTD vs. YTD | |||||||||||||||||||||||||||||||
Total Company | $ | 2,638 | $ | 2,806 | $ | 5,444 | $ | 2,170 | $ | 7,614 | $ | 2,115 | $ | 9,729 | $ | 2,505 | -5 | % | -5 | % | ||||||||||||||||||||||||||||
PHARMACEUTICALS | 2,076 | 2,205 | 4,281 | 1,619 | 5,900 | 1,517 | 7,417 | 1,944 | -6 | % | -6 | % | ||||||||||||||||||||||||||||||||||||
Cardiovascular | 1,341 | 1,330 | 2,671 | 752 | 3,423 | 616 | 4,039 | 1,045 | -22 | % | -22 | % | ||||||||||||||||||||||||||||||||||||
Plavix | 850 | 988 | 1,838 | 474 | 2,312 | 343 | 2,655 | 787 | -7 | % | -7 | % | -36 | % | -36 | % | ||||||||||||||||||||||||||||||||
Pravachol | 302 | 128 | 430 | 73 | 503 | 50 | 553 | 57 | -81 | % | -81 | % | -86 | % | -86 | % | ||||||||||||||||||||||||||||||||
Avapro/ Avalide | 139 | 167 | 306 | 159 | 465 | 182 | 647 | 163 | 17 | % | 17 | % | -1 | % | -1 | % | ||||||||||||||||||||||||||||||||
Coumadin | 47 | 46 | 93 | 45 | 138 | 48 | 186 | 38 | -19 | % | -19 | % | -17 | % | -17 | % | ||||||||||||||||||||||||||||||||
Virology | 259 | 270 | 529 | 292 | 821 | 327 | 1,148 | 319 | 23 | % | 23 | % | ||||||||||||||||||||||||||||||||||||
Reyataz | 119 | 122 | 241 | 129 | 370 | 144 | 514 | 143 | 20 | % | 20 | % | 17 | % | 17 | % | ||||||||||||||||||||||||||||||||
Sustiva Franchise***** | 108 | 115 | 223 | 128 | 351 | 144 | 495 | 144 | 33 | % | 33 | % | 25 | % | 25 | % | ||||||||||||||||||||||||||||||||
Baraclude | 9 | 9 | 18 | 14 | 32 | 18 | 50 | 17 | 89 | % | 89 | % | 127 | % | 127 | % | ||||||||||||||||||||||||||||||||
Oncology | 159 | 187 | 346 | 201 | 547 | 195 | 742 | 182 | 14 | % | 14 | % | ||||||||||||||||||||||||||||||||||||
Erbitux | 136 | 172 | 308 | 173 | 481 | 165 | 646 | 158 | 16 | % | 16 | % | N/A | N/A | ||||||||||||||||||||||||||||||||||
Taxol | 4 | 4 | 8 | 2 | 10 | 2 | 12 | 4 | — | — | N/A | N/A | ||||||||||||||||||||||||||||||||||||
Sprycel | — | — | — | 11 | 11 | 11 | 22 | 10 | — | — | N/A | N/A | ||||||||||||||||||||||||||||||||||||
Affective (Psychiatric) Disorders | 237 | 286 | 523 | 266 | 789 | 302 | 1,091 | 305 | 29 | % | 29 | % | ||||||||||||||||||||||||||||||||||||
Abilify** | 231 | 267 | 498 | 260 | 758 | 294 | 1,052 | 293 | 27 | % | 27 | % | 14 | % | 14 | % | ||||||||||||||||||||||||||||||||
Immunoscience | 5 | 18 | 23 | 34 | 57 | 31 | 88 | 40 | * | ** | * | ** | ||||||||||||||||||||||||||||||||||||
Orencia | 5 | 18 | 23 | 34 | 57 | 31 | 88 | 40 | * | ** | * | ** | N/A | N/A | ||||||||||||||||||||||||||||||||||
Other Pharmaceuticals | ||||||||||||||||||||||||||||||||||||||||||||||||
Efferalgan | — | — | — | — | — | — | — | — | — | — | N/A | N/A | ||||||||||||||||||||||||||||||||||||
NUTRITIONALS | 247 | 282 | 529 | 267 | 796 | 295 | 1,091 | 274 | 11 | % | 11 | % | ||||||||||||||||||||||||||||||||||||
Enfamil | 155 | 174 | 329 | 169 | 498 | 190 | 688 | 171 | 10 | % | 10 | % | N/A | N/A | ||||||||||||||||||||||||||||||||||
Enfagrow | — | — | — | — | — | — | — | — | — | — | N/A | N/A | ||||||||||||||||||||||||||||||||||||
OTHER HEALTH CARE | 231 | 226 | 457 | 215 | 672 | 232 | 904 | 214 | -7 | % | -7 | % | ||||||||||||||||||||||||||||||||||||
CONVATEC | 73 | 85 | 158 | 84 | 242 | 101 | 343 | 78 | 7 | % | 7 | % | ||||||||||||||||||||||||||||||||||||
Ostomy | 34 | 41 | 75 | 39 | 114 | 45 | 159 | 34 | — | — | N/A | N/A | ||||||||||||||||||||||||||||||||||||
Wound Therapeutics | 30 | 34 | 64 | 36 | 100 | 43 | 143 | 32 | 7 | % | 7 | % | N/A | N/A | ||||||||||||||||||||||||||||||||||
MEDICAL IMAGING | 158 | 141 | 299 | 131 | 430 | 131 | 561 | 136 | -14 | % | -14 | % | ||||||||||||||||||||||||||||||||||||
Cardiolite | 91 | 91 | 182 | 86 | 268 | 90 | 358 | 87 | -4 | % | -4 | % | N/A | N/A |
* | This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. |
As a result, the sum of segment sales does not tie to Total Company sales.
** | Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd. |
*** | In excess of +/- 200% |
**** | The estimated total U.S. prescription change for the retail and mail order channels are calculated based on Next-Generation Precription Services (NGPS) version 2.0 data on a weighted-average basis. NGPS data is provided by IMS Health, a supplier of market research for the pharmaceutical industry. The weighted-average basis reflects the fact that mail order prescriptions include a greater volume of product supplied compared to retail prescriptions, which on average are 90 days for mail order and 30 days for retail. The calculation is derived by multiplying NGPS mail order prescription data by a factor that approximates three and adding to this the NGPS retail prescriptions. |
***** | Beginning in the third quarter of 2006, the Sustiva Franchise includes sales of branded Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. Atripla is sold through a joint venture with Gilead Sciences, Inc. The change in U.S. total prescriptions growth for the Sustiva Franchise includes both branded Sustiva and Atripla prescription units. |
BRISTOL-MYERS SQUIBB COMPANY
U.S. PHARMACEUTICALS NET SALES
EXCLUDING ESTIMATED IMPACT OF LAUNCH OF GENERIC CLOPIDOGREL BISULFATE
($ in millions)
2007 | 2006 | % Change | |||||||
Q1 | Q1 | Qtr vs. Qtr | |||||||
U.S Pharmaceuticals Net Sales | |||||||||
U.S Pharmaceuticals Net Sales as Reported | $ | 1,932 | $ | 2,064 | -6 | % | |||
Estimated Impact of Launch of Generic Clopidogrel Bisulfate | 200 to 250 | — | — | ||||||
U.S Pharmaceuticals Net Sales Excluding the Estimated Impact of Launch of Generic Clopidogrel Bisulfate | $ | 2,132 to $2,182 | $ | 2,064 | 3% to 6 | % | |||